Press release – For immediate release – 5:45 pm CEST
Financial communication schedule for the second half of 2023
Median Technologies (Euronext Growth – ALMDT), announces the publication date for its 2023 half year results and its Q3, 2023 business performance:
| Publication | Date |
| 2023 H1 results Q3 2023 business performance | October 19, 2023 Distribution after the close of the trading |
Pioneering innovative imaging services and Software as Medical Devices, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median’s offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as medical devices (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.